Impact of Susceptibility Testing Methodology on the Positioning of Cefiderocol and Aztreonam-Avibactam Against Metallo-β-Lactamase-Producing Gram-Negative Bacteria. [PDF]
Del Nogal-Labrador F +7 more
europepmc +1 more source
Cefiderocol Is Effective In Vitro Against Numerous Gram-Negative Species Isolated from Keratitis Patients. [PDF]
Mandell JB, Shanks RMQ, Romanowski EG.
europepmc +1 more source
Cefiderocol Heteroresistance in NDM-Producing Enterobacterales: A Complex Polymicrobial Infection Successfully Salvaged With Ceftazidime-Avibactam Plus Aztreonam. [PDF]
Nuaimi M +6 more
europepmc +1 more source
A Val292 substitution combined with an alanine duplication (ADUP) in the Ω loop of ADC β-lactamase confers reduced susceptibility to advanced β-lactam agents, including cefiderocol. [PDF]
Kawai A +9 more
europepmc +1 more source
Phenotypic and genotypic characterization of HMB-3, a metallo-beta-lactamase from Pseudomonas asiatica. [PDF]
Findlay J +10 more
europepmc +1 more source
Synergistic activity of cefepime/enmetazobactam with meropenem, piperacillin, piperacillin/tazobactam, cefiderocol and fosfomycin against Klebsiella pneumoniae carrying blaKPC allelic variants. [PDF]
Crema A +3 more
europepmc +1 more source
Flow cytometry enables rapid evaluation of novel, new and niche antimicrobial agents. [PDF]
Salisbury E +6 more
europepmc +1 more source
Evidence of cefiderocol-persistence in <i>Pseudomonas aeruginosa in vitro</i> biofilms and in a murine infection model. [PDF]
Mangiaterra G +10 more
europepmc +1 more source
Cefiderocol resistance in a clinical ST11-KL64 hypervirulent Klebsiella pneumoniae isolate mediated by a novel CirA truncation and SHV-12 β-lactamase. [PDF]
Zhou P +6 more
europepmc +1 more source
The <i>in vitro</i> activity of aztreonam-avibactam and cefiderocol against globally collected clinical metallo-β-lactamase- and/or serine-carbapenemase-positive Enterobacterales isolates and the utility of commonly used <i>in vitro</i> diagnostic kits. [PDF]
Estabrook M +5 more
europepmc +1 more source

